Prelude Therapeutics (PRLD) Other Working Capital Changes (2019 - 2026)

Prelude Therapeutics has reported Other Working Capital Changes for 8 years, with the latest figure at -$4.6 million in Q1 2026.

• Quarterly Other Working Capital Changes fell 9060.0% year-over-year to -$4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.5 million (down 2146.36% YoY) and the FY2025 annual result came in at $28000.0, up 107.51% from the prior year.
• Other Working Capital Changes slipped to -$4.6 million in Q1 2026 per PRLD's latest filing, from -$1.1 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $1.2 million in Q3 2023 and troughed at -$4.6 million in Q1 2026.
• A 5-year average of -$171588.2 and a median of $355000.0 in 2023 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2025 and 2026: Other Working Capital Changes jumped 1101.83% in 2025, then tumbled 9060.0% in 2026.
• Over 5 years, Other Working Capital Changes stood at $431000.0 in 2022, then tumbled by 507.42% to -$1.8 million in 2023, then surged by 72.67% to -$480000.0 in 2024, then sank by 121.67% to -$1.1 million in 2025, then plunged by 330.45% to -$4.6 million in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered -$4.6 million, -$1.1 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.